Francesc Casas

Francesc Casas

Auto-generated profile, based on publicly available information

Francesc Casas

Radiation Oncology Department, Hospital Clínic, Barcelona, Spain.

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 1997
Verified
Journal Article
Closed access
FCF Casas
F Casas
FFF Ferrer
F Ferrer
BFB Farrús
B Farrús
JCJ Casals
J Casals
ABA Biete
A Biete

21 October 2016 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
FCF. Casas
F. Casas
IHI. Henríquez
I. Henríquez
ABA. Bejar
A. Bejar
XMX. Maldonado
X. Maldonado
AAA. Alvarez
A. Alvarez
CFC. Ferrer
C. Ferrer

20 November 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
FDF. Casas Duran
F. Casas Duran
IVI. Valduvieco
I. Valduvieco
GOG. Oses
G. Oses
KCK. S. Cortés
K. S. Cortés
TBT. D. Barreto
T. D. Barreto
FFF. Ferrer
F. Ferrer

1 October 2009 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
LKLucyna Kepka
Lucyna Kepka
ASArkadiusz Sprawka
Arkadiusz Sprawka
FCFrancesc Casas
Francesc Casas
SASherif Abdel-Wahab
Sherif Abdel-Wahab
JAJaiprakash Agarwal
Jaiprakash Agarwal
BJBranislav Jeremic
Branislav Jeremic
The combination of radiotherapy and chemotherapy is considered to be a standard approach for patients with locally advanced, stage III non-small-cell lung cancer. The current state of the art of combined radiochemotherapy supported by evidence-based data is presented. As shown in the meta-analyses, the concurrent radiochemotherapy gives a superior outcome in terms of survival compared with sequential delivery of both modalities. This is obtained at the expense of higher toxicity, which makes further intensification of radiochemotherapy challenging. Eligibility of patients with non-small-cell lung cancer for such an approach is limited. The new methods to improve treatment results, such as selection of proper strategies, incorporation of molecular agents into combined treatment and radiotherapy technique modifications are discussed.


20 August 2018 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
FCF. Casas
F. Casas
IVI. Valduvieco
I. Valduvieco
GOG. Oses
G. Oses
LILaura Izquierdo
Laura Izquierdo
IAI. Archila
I. Archila
FFF. Ferrer
F. Ferrer